Mucocutaneous Candidiasis

Stiehm's Immune Deficiencies

Volumn , Issue , 2014, Pages 775-802

  Maródi, László ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Candida; IL 17 T cell mediated immunity; Mucocutaneous candidiasis; Primary immunodeficiency disorders

Indexed keywords

EID: 84943416849     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-405546-9.00040-6     Document Type: Chapter

References (178)

1. Pfaller M.A. Epidemiology and control of fungal infections. Clin Infect Dis 1994, 19(Suppl. 1):S8-S13.
2. Levitz S.M. Overview of host defenses in fungal infections. Clin Infect Dis 1992, 14(Suppl. 1):S37-S42.
3. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010, 36:1-53.
4. Edwards J.E. Candida species. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2010, 3225-3240. Churchill Livingstone Elsevier, Philadelphia, PA. 7th ed. G.L. Mandell, J.E. Benett, R. Dolin (Eds.).
5. Knapp K.M., Flynn P.M. Candidiasis. Feigin & Cherry's Textbook of Pediatric Infectious Disesases 2009, 2741-2751. Elsevier Saunders, Philadelphia, PA. 6th ed. R.D. Feigin, J.D. Cherry, G.J. Demmler-Harrison, S.L. Kaplan (Eds.).
6. Neofytos D., Fishman J.A., Horn D., et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010, 12:220-229.
7. Maródi L., Johnston R.B. Host-fungal infections relevant to the newborn infant. Fetal and Neonatal Physiology 2011, 1566-1569. Elsevier Saunders, Philadelphia, PA. 4th ed. R.A. Polin, W.W. Fox, S.H. Abman (Eds.).
8. Maródi L. Local and systemic host defense mechanisms against candida: immunopathology of candidal infections. Pediatr Infect Dis J 1997, 16:795-801.
9. Johnston R.B. Function and cell biology of neutrophils and mononuclear phagocytes in the newborn infant. Vaccine 1998, 16:1363-1368.
10. Rezaei N., Moin M., Pourpak Z., et al. The clinical, immunohematological, and molecular study of Iranian patients with severe congenital neutropenia. J Clin Immunol 2007, 27:525-533.
11. Segal B.H., Herbrecht R., Stevens D.A., et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008, 47:674-683.
12. Cannon R.D., Holmes A.R., Mason A.B., Monk B.C. Oral Candida: clearance, colonization, or candidiasis?. J Dent Res 1995, 74:1152-1161.
13. Prentice A.G. Oral and gastrointestinal candidosis: prophylaxis during immunosuppressive therapy. Mycoses 1989, 32(Suppl. l):42-46.
14. Candida and Candidosis 1988, Baillière Tindall, London. 2nd ed. F.C. Odds (Ed.).
15. Gergely L., Uri J. Day-by-day variation in the mycotic flora of the mouth. Arch Oral Biol 1966, 11:15-19.
16. Hostetter M.K. RGD-mediated adhesion in fungal pathogens of humans, plants and insects. Curr Opin Microbiol 2000, 3:344-348.
17. Hostetter M.K. The iC3b receptor of Candida albicans and its roles in pathogenesis. Vaccine 2008, 26(Suppl. 8):108-112.
18. Ravanfar P., Wallace J.S., Pace N.C. Diaper dermatitis: a review and update. Curr Opin Pediatr 2012, 24:472-479.
19. Caramalac D.A., da Silva Ruiz L., de Batista G.C., et al. Candida isolated from vaginal mucosa of mothers and oral mucosa of neonates: occurrence and biotypes concordance. Pediatr Infect Dis J 2007, 26:553-557.
20. Nishimura S., Nagata N., Shimbo T., et al. Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy. PLoS ONE 2013, 8:e5821.
21. Ang B.S., Telenti A., King B., et al. Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis 1993, 17:662-666.
22. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369:1961-1971.
23. Jaeger M., Plantinga T.S., Joosten L.A., et al. Genetic basis for recurrent vulvo-vaginal candidiasis. Curr Infect Dis Rep 2013, 15:136-142.
24. Guclu O., Ulkumen B., Bulbul T. Candida laryngitis. Otolaryngol Head Neck Surg 2006, 135:483-484.
25. Malton A., DeFatta R.A., Sataloff R.T. Acute candidal pharyngolaryngitis. Ear Nose Throat J 2012, 91:E31-E32.
26. Kabe J., Aoki K., Ishizaki T., et al. Relationship of dermal and pulmonary sensitivity to extracts of Candida albicans. Am Rev Respir Dis 1971, 104:348-357.
27. Gelotar P., Vachhani S., Patel B., et al. The prevalence of fungi in fingernail onychomycosis. J Clin Diagn Res 2013, 7:250-252.
28. Alvaro-Meca A., Jensen J., Micheloud D., Díaz A., Gurbindo D., Resino S. Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008). BMC Infect Dis 2013, 4(13):115.
29. Lortholary O., Petrikkos G., Akova M., et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 2012, 18(Suppl. 7):68-77.
30. Nyirjesy P., Zhao Y., Ways K., Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012, 28:1173-1178.
31. Sardi J.C., Duque C., Mariano F.S., Marques M.R., Höfling J.F., Gonçalves R.B. Adhesion and invasion of Candida albicans from periodontal pockets of patients with chronic periodontitis and diabetes to gingival human fibroblasts. Med Mycol 2012, 50:43-49.
32. Chen C.Y., Huang S.Y., Tsay W., et al. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010. Int J Antimicrob Agents 2012, 40:533-538.
33. Maródi L., Cypowyj S., Tóth B., et al. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol 2012, 130:1019-1027.
34. Puel A., Cypowyj S., Maródi L., et al. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012, 12:616-622.
35. Cypowyj S., Picard C., Maródi L., et al. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol 2012, 42:2246-2254.
36. Stockinger B., Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007, 19:281-286.
37. Chen Z., Laurence A., O'Shea J.J. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Cytokine Growth Factor Rev 2007, 19:400-408.
38. McGeachy M.J., Cua D.J. Th17 cell differentiation: the long and winding road. Immunity 2008, 28:445-453.
39. Marks B.R., Nowyhed H.N., Choi J.Y., et al. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol 2009, 10:1125-1132.
40. Zhou L., Littman D.R. Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol 2009, 21:146-152.
41. Hirahara K., Ghoreschi K., Laurence A., et al. Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 2010, 21:425-434.
42. May M.J. IL-17R signaling: new players get in on the Act1. Nat Immunol 2011, 12:813-815.
43. Sallusto F., Zielinski C.E., Lanzavecchia A. Human Th17 subsets. Eur J Immunol 2012, 42:2215-2220.
44. Ness-Schwickerath K.J., Jin C., Morita C.T. Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J Immunol 2010, 184:7268-7280.
45. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10:479-489.
46. Gaffen S.L. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011, 23:613-619.
47. Hardison S.E., Brown G.D. C-type lectin receptors orchestrate antifungal immunity. Nat Immunol 2012, 13:817-822.
48. Puel A., Cypowyj S., Bustamante J., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332:65-68.
49. Liu L., Okada S., Kong X.F., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011, 208:1635-1648.
50. van deVeerdonk F.L., Plantinga T.S., Hoischen A., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011, 365:54-61.
51. Tóth B., Méhes L., Taskó S., et al. Herpes in STAT1 mutation. Lancet 2012, 380:806.
52. Smeekens S.P., Plantinga T.S., van de Veerdonk F.L., et al. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS ONE 2011, 6:e29248.
53. Hori T., Ohnishi H., Teramoto T., et al. Autosomal-dominant chronic mucocutaneous candidiasis with STAT1-mutation can be complicated with chronic active hepatitis and hypothyroidism. J Clin Immunol 2012, 32:1213-1220.
54. Takezaki S., Yamada M., Kato M., et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol 2012, 189:1521-1526.
55. Buckley R.H. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000, 343:1313-1324.
56. Maródi L., Notarangelo L.D. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol 2007, 7:851-861.
57. Fischer A. Human primary immunodeficiency diseases. Immunity 2007, 27:835-845.
58. Notarangelo L.D. Functional T cell immunodeficiencies (with T cells present). Annu Rev Immunol 2013, 31:195-225.
59. Roifman C.M., Somech R., Kavadas F., et al. Defining combined immunodeficiency. J Allergy Clin Immunol 2012, 130:177-183.
60. Al-Herz W., Bousfiha A., Casanova J.L., et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol 2011, 2:54.
61. Feske S., Müller J.M., Graf D., et al. Severe combined immunodeficiency due to defective binding of nuclear factor of activated T cells in T lymphocytes of two male siblings. Eur J Immunol 1996, 26:2119-2126.
62. Hogan P.G., Rao A. Dissecting ICRAC, a store-operated calcium current. Trends Biochem Sci 2007, 32:235-245.
63. Feske S., Gwack Y., Prakriya M., et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006, 441:179-185.
64. Zhang Q., Davis J.C., Lamborn I.T., et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009, 36:2046-2055.
65. Engelhardt K., McGhee S., Winkler S., et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol 2009, 124:1289-1302.
66. Zhang Q., Davis J.C., Dove C.G., Su H.C. Genetic, clinical, and laboratory markers for DOCK8 immunodeficiency syndrome. Dis Markers 2010, 29:131-139.
67. Su H.C. Dedicator of cytokeneisis 8 (DOCK8) deficiency. Curr Opin Allergy Clin Immunol 2010, 10:515-520.
68. Freeman A.F., Holland S.M. Clinical manifestations of hyper IgE syndromes. Dis Markers 2010, 29:123-130.
69. Randall K.L., Chan S.S., Ma C.S., et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med 2011, 24:2305-2320.
70. Lambe T., Crawford G., Johnson A.L., et al. DOCK8 is essential for T-cell survival and the maintenance of CD8+ T-cell memory. Eur J Immunol 2011, 41:3423-3435.
71. Randall K.L., Lambe T., Goodnow C.C., et al. The essential role of DOCK8 in humoral immunity. Dis Markers 2010, 29:141-150.
72. Jabara H.H., McDonald D.R., Janssen E., et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol 2012, 13:612-620.
73. Chu E.Y., Freeman A.F., Jing H., et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 2012, 148:79-84.
74. Sanal O., Jing H., Ozgur T., et al. Additional diverse findings expand the clinical presentation of DOCK8 deficiency. J Clin Immunol 2012, 32:698-708.
75. Rezaei N., Hedayat M., Aghamohammadi A., Nichols K.E. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol 2011, 127:1329-1341.
76. McDonald D.R., Massaad M.J., Johnston A., et al. Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal-recessive hyper-IgE syndrome caused by dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2010, 126:1304-1305.
77. Perheentupa J. Autoimmunepolyendocrinopathy Candidiasis Ectodermal Dystrophy. J Clin Endocrinol Metab 2006, 91:2843-2850.
78. Husebye E.S., Perheentupa J., Rautemaa R., Kämpe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 2009, 265:514-529.
79. The Finnish-German APECED Consortium An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. The Finnish-German APECED Consortium. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Nat Genet 1997, 17:399-403.
80. Nagamine K., Peterson P., Scott H.S., et al. Positional cloning of the APECED gene. Nat Genet 1997, 17:393-398.
81. Jiao H., Tóth B., Erdös M., et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol 2008, 46:202-206.
82. Zlotogora J., Shapiro M.S. Polyglandular autoimmune syndrome type I among Iranian Jews. J Med Genet 1992, 29:824-826.
83. Rosatelli M.C., Meloni A., Devoto M., et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum Genet 1998, 103:428-434.
84. Wolff A.S., Erichsen M.M., Meager A., et al. Autoimmune polyendocrine syndrome type I (APS I) in Norway-phenotypic variation, autoantibodies and novel mutations in the autoimmune regulator (AIRE) gene. J Clin Endocrinol Metab 2007, 92:595-603.
85. Dominguez M., Crushell E., Ilmarinen T., et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in the Irish population. J Pediatr Endocrinol Metab 2006, 19:1343-1352.
86. Cihakova D., Trebusak K., Heino M., et al. Novel AIRE mutations and P450 cytochrome autoantibodies in Central and Eastern European patients with APECED. Hum Mutat 2001, 18:225-232.
87. Björses P., Halonen M., Palvimo J.J., et al. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am J Hum Genet 2000, 66:378-392.
88. Wang C.Y., Davoodi-Semiromi A., Huang W., Connor E., Shi J.D., She J.X. Characterization of mutations in patients with autoimmune polyglandular syndrome type I (APS I). Hum Genet 1998, 103:681-685.
89. Heino M., Scott H.S., Chen Q., et al. Mutation analyses of North American APS-I patients. Hum Mutat 1999, 13:69-74.
90. Scott H.S., Heino M., Peterson P., et al. Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol 1998, 12:1112-1119.
91. Sato U., Horikawa R., Katsumata N., Asakura Y., Kitanaka S., Tanaka T. Novel compound heterozygous AIRE mutations in a Japanese patient with APECED. J Pediatr Endocrinol Metab 2004, 17:917-921.
92. Pearce S.H., Cheetham T., Imrie H., et al. A common and recurrent 13-bp deletion in the autoimmune regulator gene in British kindreds with autoimmune polyendocrinopathy type I. Am J Hum Genet 1998, 63:1675-1684.
93. Mathis D., Benoist C. Aire. Annu Rev Immunol 2009, 27:287-312.
94. Peterson P., Peltonen L. Autoimmunepolyendocrinopathy syndrome type I (APS I) and AIRE gene: new views on molecular basis of autoimmunity. J Autoimmun 2005, 25:49-55.
95. Meager A., Visvalingam K., Peterson P., et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type I. PLoS Med 2006, 3:1152-1164.
96. Meloni A., Furcas M., Cetani F., et al. Autoantibodies against type I interferon as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008, 93:4389-4397.
97. Oftedal B.E., Bøe Wolff A.S., Bratland E., et al. Radioimmunoassay for autoantibodies against interferon omega, its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol 2008, 129:163-169.
98. Puel A., Döffinger R., Natividad A., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010, 207:291-297.
99. Kisand K., Bøe Wolff A.S., Podkrajsek K.T., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010, 207:299-308.
100. Kisand K., Lilic D., Casanova J.L., Peterson P., Meager A., Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol 2011, 41:1517-1527.
101. Gardner J.M., Devoss J.J., Friedman R.S., et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 2008, 321:843-847.
102. Perheentupa J. APS-I/APECED: the clinical disease and therapy. Endocrinol Metab Clin North Am 2002, 31:295-320.
103. Wolff A., Sarkadi A.K., Maródi L., et al. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J Clin Immunol 2013, 33(8):1341-1348.
104. Sarkadi A.K., Taskó S., Csorba G. Autoantibodies to IL-17a may be correlated with the severity of mucocutaneous candidiasis in APECED patients. J Clin Immunol 2014, 34:181-193.
105. Blizzard R.M., Kyle M. Studies of the adrenal antigens and the antibodies in Addison's disease. J Clin Invest 1963, 42:1653-1660.
106. Alimohammadi M., Björklund P., Hallgren A., et al. Autoimmune polyendocrine syndrome type I and NALP5, a parathyroid autoantigen. N Engl J Med 2008, 358:1018-1028.
107. Söderbergh A., Myhre A.G., Ekwall O., et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2004, 89:557-562.
108. Gylling M., Tuomi T., Björses P., et al. β-cell autoantibodies, human leukocyte antigen II alleles, and type I diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab 2000, 85:4434-4440.
109. Husebye E.S., Gebre-Medhin G., Gustafsson J., et al. Cytochrome P4501A2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I. FEBS Lett 1997, 412:439-445.
110. Capalbo D., Fusco A., Aloj G., et al. High intrafamilial variability in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case study. J Endocrinol Invest 2012, 35:77-81.
111. Rautemaa R., Hietanen J., Niissalo S., et al. Oral and oesophageal squamous cell carcinoma - A complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol 2007, 43:607-613.
112. Tazi-Ahnini R., McDonagh A.J., Wengraf D.A., et al. The autoimmune regulator gene (AIRE) is strongly associated with vitiligo. Br J Dermatol 2008, 159:591-596.
113. Ahonen P., Myllärniemi S., Sipilä I., Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990, 322:1829-1836.
114. Zauli D., Tosti A., Biasco G., et al. Prevalence of autoimmune atrophic gastritis in vitiligo. Digestion 1986, 34:169-172.
115. Betterle C., Del Prete G.F., Peserico A., et al. Autoantibodies in vitiligo. Arch Dermatol 1976, 112:1328.
116. Gupta A.N., Nagri S.K. Schmidt's syndrome - case report. Australas Med J 2012, 5:292-295.
117. Rautemaa R., Richardson M., Pfaller M., Perheentupa J., Saxen H. Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole. Scand J Infect Dis 2008, 40:904-907.
118. Glocker E.O., Hennings A., Nabavi M., et al. A homozygous CARD9 mutation in family with susceptibility to fungal infections. N Engl J Med 2009, 361:1727-1735.
119. Drewniak A., Gazendam R.P., Tool A.T., et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 2013, 121:2385-2392.
120. Lanternier F., Pathan S., Vincent Q., et al. Human deep dermatophytosis is caused by inborn errors of CARD9. J Clin Immunol 2012, 32(Suppl. 1):72.
121. Bertin J., Guo Y., Wang L., Srinivasula S.M., et al. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B. J Biol Chem 2000, 275:41082-41086.
122. Bi L., Gojestani S., Wu W., et al. CARD9 mediates dectin-2-induced IkappaBalpha kinase ubiquitination leading to activation of NF-kappaBin response to stimulation by the hyphal form of Candida albicans. J Biol Chem 2010, 285:25969-25977.
123. Hara H., Ishihara C., Takeuchi A., et al. The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol 2007, 8:619-629.
124. Maródi L., Korchak H.M., Johnston R.B. Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol 1991, 146:2783-2789.
125. Degreef H. Clinical forms of dermatophytosis (ringworm infection). Mycopathologia 2008, 166:257-265.
126. Liautaud B., Marill F.G. Dermatophytic disease. Recent Algerian observations. Bull Soc Pathol Exot Filiales 1984, 77:637-648.
127. Marconi V.C., Kradin R., Marty F.M., Hospenthal D.R., Kotton C.N. Disseminated dermatophytosis in a patient with hereditary hemochromatosis and hepatic cirrhosis: case report and review of the literature. Med Mycol 2010, 48:518-527.
128. Altare F., Durandy A., Lammas D., et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998, 280:1432-1435.
129. de Jong R., Altare F., Haagen I.A., et al. Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients. Science 1998, 280:1435-1438.
130. Altare F., Lammas D., Revy P., et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection. J Clin Invest 1998, 102:2035-2040.
131. de Beaucoudrey L., Samarina A., Bustamante J., et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine 2010, 89:381-402.
132. Prando C., Samarina A., Bustamante J., et al. Inherited IL-12p40deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine 2013, 92:109-122.
133. Filipe-Santos O., Bustamante J., Chapgier A., et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006, 18:347-361.
134. Casanova J.L., Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002, 20:581-620.
135. Dorman S.E., Holland S.M. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000, 11:321-333.
136. Zonana J., Elder M.E., Schneider L.C., et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 2000, 67:1555-1562.
137. Ku C.L., Yang K., Bustamante J., et al. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 2005, 203:10-20.
138. Bustamante J., Picard C., Fieschi C., et al. A novel X-linked recessive form of Mendelian susceptibility to mycobaterial disease. J Med Genet 2007, 44:e65.
139. Soltész B., Tóth B., Shabashova N., et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet 2013, 50(9):567-578.
140. van de Veerdonk F.L., Plantinga T.S., Hoischen A., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011, 365:54-61.
141. Puel A., Picard C., Cypowyj S., Lilic D., Abel L., Casanova J.L. Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines?. Curr Opin Immunol 2010, 22:467-474.
142. Chilgren R.A., Quie P.G., Meuwissen H.J., Hong R. Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect. Lancet 1967, 2:688-693.
143. Canales L., Middlemas R.O., Louro J.M., South M.A. Immunological observations in chronic mucocutaneous candidiasis. Lancet 1969, 2:567-571.
144. Wells R.S., Higgs J.M., Macdonald A., Valdimarsson H., Holt P.J. Familial chronic muco-cutaneous candidiasis. J Med Genet 1972, 9:302-310.
145. Averbuch D., Chapgier A., Boisson-Dupuis S., Casanova J.L., Engelhard D. The clinical spectrum of patients with deficiency of signal transducer and activator of transcription-1. Pediatr Infect Dis J 2011, 30:352-355.
146. Takezaki S., Yamada M., Kato M., Park M.J., Maruyama K., Yamazaki Y. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol 2012, 189:1521-1526.
147. Uzel G., Sampaio E.P., Lawrence M.G., et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 2013, 131(6):1611-1623.
148. Sampaio E.P., Hsu A.P., Pechacek J., et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 2013, 131(6):1624-1634.
149. Tóth B., Méhes L., Taskó S., Szalai Z., Tulassay Z., Cypowyj S., et al. Herpes in STAT1 mutation. Lancet 2012, 379:2500.
150. Al-Muhsen S., Casanova J.L. The genetic heterogeneity of Mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008, 122:1043-1051.
151. Boisson-Dupuis S., Kong X.F., Okada S., et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol 2012, 24:364-378.
152. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
153. O'Shea J.J., Lahesmaa R., Vahedi G., Laurence A., Kanno Y. Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol 2011, 11:239-250.
154. Casanova J.L., Holland S.M., Notarangelo L.D. Inborn errors of human JAKs and STATs. Immunity 2012, 36:515-528.
155. Milner J.D., Brenchley J.M., Laurence A., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
156. Rice G.I., Kasher P.R., Forte G.M., et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet 2012, 44:1243-1248.
157. Briggs T.A., Rice G.I., Daly S., et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet 2011, 43:127-131.
158. Selmi C., Lleo A., Zuin M., Podda M., Rossaro L., Gershwin M.E. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 2006, 7:451-456.
159. Zheng R.Q., Abney E.R., Grubeck-Loebenstein B., Dayan C., Maini R.N., Feldmann M. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. J Autoimmun 1990, 3:727-736.
160. Naik S.M., Shibagaki N., Li L.J., Quinlan K.L., Paxton L.L., Caughman S.W. Interferon gamma-dependent induction of human intercellular adhesion molecule-1 gene expression involves activation of a distinct STAT protein complex. J Biol Chem 1997, 272:1283-1290.
161. Caughman S.W., Li L.J., Degitz K. Characterization and functional analysis of interferon-gamma-induced intercellular adhesion molecule-1 expression in human keratinocytes and A-431 cells. J Invest Dermatol 1990, 94(Suppl. 6):S22-S26.
162. Kita H., Mackay I.R., Van De Water J., Gershwin M.E. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001, 120:1485-1501.
163. Hong F., Jaruga B., Kim W.H., et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 2002, 110:1503-1513.
164. Ferwerda B., Ferwerda G., Plantinga T.S., et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009, 361:1760-1767.
165. Plato A., Willment J.A., Brown G.D. C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int Rev Immunol 2013, 32:134-156.
166. Maródi L., Erdös M. Dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2010, 362:7.
167. Netea M.G., van der Meer J.W. Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med 2011, 364:60-70.
168. Vautier S., MacCallum D.M., Brown G.D. C-type lectin receptors and cytokines in fungal immunity. Cytokine 2012, 58:89-99.
169. Netea M.G., Maródi L. Innate immune mechanisms for recognition and uptake of Candida species. Trends Immunol 2010, 31:346-353.
170. Drummond R.A., Saijo S., Iwakura Y., Brown G.D. The role of Syk/CARD9 coupled C-type lectins in antifungal immunity. Eur J Immunol 2011, 41:276-281.
171. Bugarcic A., Hitchens K., Beckhouse A.G., Wells C.A., Ashman R.B., Blanchard H. Human and mouse macrophage-inducible C-type lectin (Mincle) bind Candida albicans. Glycobiology 2008, 18:679-685.
172. Cambi A., Netea M.G., Mora-Montes H.M., et al. Dendritic cell interaction with Candida albicans critically depends on N-linked mannan. J Biol Chem 2008, 283:20590-20599.
173. Maródi L., Forehand J.R., Johnston R.B. Mechanisms of host defense against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J Immunol 1991, 146:2790-2794.
174. Maródi L., Schreiber S., Anderson D.C., MacDermott R.P., Korchak H.M., Johnston R.B. Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest 1993, 91:2596-2601.
175. Maródi L., Casanova J.L. Primary immunodeficiencies: the J Project. Lancet 2009, 373:2179-2181.
176. Maródi L., Notarangelo L.D. Education and world wide collaboration pays off. Nat Immunol 2007, 8:323-324.
177. Maródi L., J Project Study Group The creation and progress of the J Project in Eastern and Central Europe. Ann NY Acad Sci 2011, 1238:65-73.
178. Horváth Z., Rezaei N., Reisli I., et al. The spread of the J Project. J Clin Immunol 2013, 33:1037-1042.